ProKidney (PROK) Expected to Post Earnings on Monday

by · The Cerbat Gem

ProKidney (NASDAQ:PROK – Get Free Report) is anticipated to post its Q3 2026 resultson Monday, November 9th. Analysts expect ProKidney to announce earnings of ($0.13) per share and revenue of $0.12 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

ProKidney (NASDAQ:PROK – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.19 million. On average, analysts expect ProKidney to post ($0.51) EPS for the current fiscal year and ($0.75) EPS for the next fiscal year.

ProKidney Stock Performance

NASDAQ:PROK opened at $1.29 on Monday. The stock has a 50 day simple moving average of $1.67 and a 200 day simple moving average of $1.82. The stock has a market cap of $391.50 million, a P/E ratio of -2.35 and a beta of 1.90. ProKidney has a 1-year low of $1.29 and a 1-year high of $3.13.

Insider Transactions at ProKidney

In other news, Director Brian Pereira sold 229,338 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $1.37, for a total value of $314,193.06. Following the transaction, the director owned 445,897 shares in the company, valued at approximately $610,878.89. The trade was a 33.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 757,164 shares of company stock worth $1,067,315. 39.83% of the stock is currently owned by company insiders.

Analyst Ratings Changes

PROK has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of ProKidney in a research report on Tuesday, October 6th. Citigroup lowered their price objective on shares of ProKidney to $8.00 and set a “buy” rating for the company in a research report on Wednesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, ProKidney has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Get Our Latest Stock Analysis on ProKidney

About ProKidney

(Get Free Report)

ProKidney Corporation is a biotechnology company focused on developing cell-based therapies for chronic kidney disease (CKD). The company’s lead investigational product is rilparencel, formerly known as REACT, an autologous cell therapy made from a patient’s own kidney cells.

Rilparencel is designed to be injected into the patient’s kidneys, where the cells are intended to support kidney function and potentially slow the progression of CKD. ProKidney is studying the therapy primarily in patients with diabetic kidney disease and advanced CKD, with the goal of delaying or reducing the need for dialysis or kidney transplantation.

ProKidney’s operations are centered on the development and clinical testing of rilparencel, and the company does not currently have an approved commercial product.

See Also